MedTrace Logo

The iCat2, GAIN (Genomic Assessment Informs Novel Therapy) Consortium Study

NCT02520713 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 825

Last updated 2026-04-28

No results posted yet for this study

Summary

This research study is evaluating the use of specialized testing of solid tumors including sequencing. The process of performing these specialized tests is called tumor profiling. The tumor profiling may result in identifying changes in genes of the tumor that indicate that a particular therapy may have activity. This is called an individualized cancer therapy (iCat) recommendation. The results of the tumor profiling and, if applicable, the iCat recommendation will be returned.

Conditions

  • Pediatric Solid Tumor

Interventions

GENETIC

Genetic testing and GAIN report

All patients enrolled will submit specimens for genetic analysis. If successful the report will be reviewed to look for possible recommendations and a GAIN report will be generated regardless of possible recommendations.

Sponsors & Collaborators

Principal Investigators

  • Katherine Janeway, MD · Dana-Farber Cancer Institute

Eligibility

Max Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2026-06-30
Completion
2026-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02520713 on ClinicalTrials.gov